Evidence map›Paper›PMID 34205096›Full record

ArticlePathogens (Basel, Switzerland)2021

High Rates of Hidden HCV Infections among Hospitalized Patients Aged 55-85.

Annarita Valeria Piazzolla, Giulia Paroni, Francesca Bazzocchi, Mauro Cassese, Antonio Cisternino, Luigi Ciuffreda, Franco Gorgoglione, Leonardo Gorgoglione, Vincenzo Palazzo, Natale Sciannamè and 15 more

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. The long-term effect of COVID-19 infection on olfaction and taste; a prospective analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Observational
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 1 institution in 1 country.

Annarita Valeria PiazzollaLiver Unit, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Giulia ParoniBlood Bank, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Francesca BazzocchiAbdominal Surgery, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Mauro CasseseCardiosurgery, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Antonio CisterninoUrology, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Luigi CiuffredaBreast Surgery, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Franco GorgoglioneOrthopedics, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Leonardo GorgoglioneNeurosurgery, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Vincenzo PalazzoVascular Surgery, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Natale SciannamèGynaecology, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Marco TaurchiniThoracic Surgery, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Pasquale VairaIntensive Care, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Giovanna CocomazziLiver Unit, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Maria Maddalena SquillanteLiver Unit, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Filippo AucellaNephrology, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Nicola CascavillaHematology, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Salvatore De CosmoInternal Medicine, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Michelantonio FaniaDermatology, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Antonio GrecoGeriatrics, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Antonio LaboranteOftalmology, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Maurizio LeoneNeurology, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.ORCID 0000-0002-6339-5738
Evaristo MaielloOncology, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Mauro SalvatoriCardiology, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Lazzaro Di MauroBlood Bank, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Alessandra MangiaLiver Unit, IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.ORCID 0000-0002-2600-3555
Casa Sollievo della Sofferenza · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsThe WHO has solicited all countries to eliminate HCV by 2030. The Italian government started routine screening for HCV infection in January 2021, initially targeting subjects born between 1969 and 1989. With the aim of achieving micro-elimination, we designed a hospital-wide project focusing on inpatients born from 1935 to 1985 and conducted it in our institution.

methodAll inpatients aged 35 to 85, admitted from 10 February 2020 to 9 February 2021 for many different diseases and conditions underwent HCV antibody (HCVAb) testing by third-generation ELISA. When positive, reflex HCV RNA testing and genotyping were performed. Clinical history, fibrosis diagnosis, laboratory data and concomitant medications were available for all.

resultsThe HCV screening rate of inpatients was 100%. In total, 11,748 participants were enrolled, of whom 53.50% were male. The HCVAb positivity rate was 3.03%. The HCVAb rate increased with age and was higher for patients born between 1935 and 1944 (4.81%). The rate of HCV RNA positivity was 0.97%. The vast majority (80.70%) of HCV RNA-positive participants were 55 or older; in about 40% of cases, HCV RNA-positive patients were unaware of their infection. Although 16 patients died after HCV chronic infection diagnosis (two due COVID-19) or HCV treatment prescription (one due to COVID-19), 74.56% of patient HCV diagnoses were linked to HCV treatment, despite their co-morbidities. All patients older than 65 who died had an active HCV infection.

conclusionThe present study revealed a rate of active HCV infections among inpatients lower than what has been reported in the past in the general population; this appears to be a result of the widespread use of pangenotypic direct-acting antiviral agents (DAAs). The overall rate of active infection was lower than the rate observed in the 1935-1954 cohort. The high rate of inpatients unaware of HCV infections and the high number of deaths among subjects with an active HCV infection born from 1935 to 1954, suggest that, at least in southern Italy, targeted screening of this birth cohort may be required to reduce the number of undiagnosed cases and hidden infections.

Indexed as

birth cohortHCVlinkage-to-caremicro-eliminationscreeningsofosbuvir/velpatasvir

Identifiers

PMID34205096
PMCPMC8227146
OpenAlexW3167769921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.